0001127602-23-018126.txt : 20230607
0001127602-23-018126.hdr.sgml : 20230607
20230607160539
ACCESSION NUMBER: 0001127602-23-018126
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230605
FILED AS OF DATE: 20230607
DATE AS OF CHANGE: 20230607
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Garay Arpa
CENTRAL INDEX KEY: 0001916360
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 23999005
MAIL ADDRESS:
STREET 1: 2000 GALLOPING HILL RD
CITY: KENILWORTH
STATE: NJ
ZIP: 07033
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0407
4
2023-06-05
0001682852
Moderna, Inc.
MRNA
0001916360
Garay Arpa
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
1
Chief Commercial Officer
1
Common Stock
2023-06-05
4
M
0
4562
A
4837
D
Common Stock
2023-06-06
4
S
0
2290
125.7518
D
2547
D
Restricted Stock Units
2023-06-05
4
M
0
4562
0
D
Common Stock
4562
13686
D
Restricted stock units convert into common stock on a one-for-one basis.
Includes 275 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on May 31, 2023.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
25% of the shares subject to this restricted stock unit award vested on June 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
/s/ James Dillon, as Attorney-in-Fact
2023-06-07